JP2010189318A - 血流改善剤 - Google Patents
血流改善剤 Download PDFInfo
- Publication number
- JP2010189318A JP2010189318A JP2009035658A JP2009035658A JP2010189318A JP 2010189318 A JP2010189318 A JP 2010189318A JP 2009035658 A JP2009035658 A JP 2009035658A JP 2009035658 A JP2009035658 A JP 2009035658A JP 2010189318 A JP2010189318 A JP 2010189318A
- Authority
- JP
- Japan
- Prior art keywords
- blood flow
- improving agent
- water
- flow improving
- filling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000017531 blood circulation Effects 0.000 title claims abstract description 85
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 113
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 57
- 239000002101 nanobubble Substances 0.000 claims abstract description 54
- 150000002894 organic compounds Chemical class 0.000 claims abstract description 35
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 33
- 235000010755 mineral Nutrition 0.000 claims abstract description 33
- 239000011707 mineral Substances 0.000 claims abstract description 33
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000001301 oxygen Substances 0.000 claims abstract description 30
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 30
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 claims abstract description 29
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 claims abstract description 28
- 150000001413 amino acids Chemical class 0.000 claims abstract description 28
- 239000002509 fulvic acid Substances 0.000 claims abstract description 28
- 229940095100 fulvic acid Drugs 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 25
- 239000011573 trace mineral Substances 0.000 claims abstract description 20
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 20
- 235000013311 vegetables Nutrition 0.000 claims abstract description 5
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 29
- 238000011049 filling Methods 0.000 claims description 28
- 235000001014 amino acid Nutrition 0.000 claims description 27
- 239000008213 purified water Substances 0.000 claims description 26
- 239000012528 membrane Substances 0.000 claims description 15
- 238000001223 reverse osmosis Methods 0.000 claims description 15
- -1 tricylina Chemical compound 0.000 claims description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004473 Threonine Substances 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 229960003067 cystine Drugs 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 239000010438 granite Substances 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 11
- 238000001784 detoxification Methods 0.000 abstract description 4
- 230000029142 excretion Effects 0.000 abstract description 4
- 230000000295 complement effect Effects 0.000 abstract description 3
- 238000000354 decomposition reaction Methods 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 231100000167 toxic agent Toxicity 0.000 abstract description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 abstract 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 239000000306 component Substances 0.000 description 16
- 239000002245 particle Substances 0.000 description 12
- 239000000126 substance Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 239000011630 iodine Substances 0.000 description 7
- 229910052740 iodine Inorganic materials 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 229910001385 heavy metal Inorganic materials 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241001474374 Blennius Species 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000035784 germination Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000005486 organic electrolyte Substances 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036782 biological activation Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 150000002013 dioxins Chemical class 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
【解決手段】酸素が溶存するナノバブル水に、ナノコロイド化されてなる海洋性有機化合物と、鉱石から抽出されナノコロイド化されてなるミネラルを含む複数の微量元素と、ナノコロイド化されてなる、フルボ酸由来の植物性のミネラルおよびアミノ酸とが配合されてなる。
【選択図】なし
Description
(1)逆浸透膜装置で純水を精製する工程と、
(2)(1)の工程で得られた精製水を容器に充填する工程と、
(3)ナノコロイド化された海洋性有機化合物を前記精製水に充填する工程とからなる、血流改善剤の製造方法である。
(1)逆浸透膜装置で純水を精製する工程と、
(2)(1)の工程で得られた精製水を容器に充填する工程と、
(3)ナノコロイド化された海洋性有機化合物、フルボ酸由来の植物性のミネラルおよびアミノ酸を前記精製水に充填する工程とからなる、血流改善剤の製造方法である。
(1)逆浸透膜装置で純水を精製する工程と、
(2)(1)の工程で得られた精製水を容器に充填する工程と、
(3)ナノコロイド化された海洋性有機化合物と、フルボ酸由来の植物性のミネラルおよびアミノ酸と、微量元素を前記精製水に充填する工程とからなる、血流改善剤の製造方法である。
(1)逆浸透膜装置で純水を精製した後、精製した純水をマイクロ・ナノバブル生成装置(BUVITAS(株)協和機設製)を使用し、酸素を溶存させたナノバブル水を調整した。このとき、溶存酸素と溶存オゾンの比は、およそ80〜90ppmであった。(2)生成された酸素またはオゾンを溶存させたナノバブル水で充填容器を洗浄した後、容器に充填し、(3)海洋性有機化合物を、ナノバブル水1.000ミリリットルに対して、2ミリリットル液量充填した後、容器をキャッピングした。
前記ナノバブル水のかわりに精製水を使用し、(2)の工程のうち容器を洗浄する工程を省略した以外は、実施例1と同様に調製した。
(1)逆浸透膜装置で純水を精製した後、精製した純水をマイクロ・ナノバブル生成装置(BUVITAS(株)協和機設製)を使用し、酸素を溶存させたナノバブル水を調整した。このとき、溶存酸素と溶存オゾンの比は、およそ80〜90ppmであった。(2)生成された酸素またはオゾンを溶存させたナノバブル水で充填容器を洗浄した後、容器に充填し、(3)海洋性有機化合物を、ナノバブル水1.000ミリリットルに対して、2ミリリットル液量充填し、フルボ酸由来の植物性のミネラルおよびアミノ酸を、ナノバブル水1.000ミリリットルに対して、5ミリリットル充填した後、容器をキャッピングした。
前記ナノバブル水のかわりに精製水を使用し、(2)の工程のうち容器を洗浄する工程を省略した以外は、実施例3と同様に調製した。
(1)逆浸透膜装置で純水を精製した後、精製した純水をマイクロ・ナノバブル生成装置(BUVITAS(株)協和機設製)を使用し、酸素を溶存させたナノバブル水を調整した。このとき、溶存酸素と溶存オゾンの比は、およそ80〜90ppmであった。(2)生成された酸素またはオゾンを溶存させたナノバブル水で充填容器を洗浄した後、容器に充填し、(3)海洋性有機化合物を、ナノバブル水1.000ミリリットルに対して、2ミリリットル液量充填し、微量元素を、ナノバブル水1.000ミリリットルに対して、3ミリリットル液量充填し、フルボ酸由来の植物性のミネラルおよびアミノ酸を、ナノバブル水1.000ミリリットルに対して、5ミリリットル充填した後、容器をキャッピングした。
前記ナノバブル水のかわりに精製水を使用し、(2)の工程のうち容器を洗浄する工程を省略した以外は、実施例5と同様に調製した。
実施例5について、(3)の工程のうち、海洋性有機化合物、微量元素およびフルボ酸由来の植物性のミネラルおよびアミノ酸を添加せずに容器をキャッピングした以外は、実施例5と同様に調製した。
実施例1、2および比較例1について
毛細血管での血流活性を、レーザードップラー装置によって評価した。
2 実施例2の血流改善剤の血流上昇値
3 実施例3の血流改善剤の血流上昇値
4 実施例4の血流改善剤の血流上昇値
5 実施例5の血流改善剤の血流上昇値
6 実施例6の血流改善剤の血流上昇値
7 比較例1の血流改善剤の血流上昇値
Claims (11)
- 水に、ナノコロイド化された海洋性有機化合物が配合されてなる血流改善剤。
- ナノコロイド化されたフルボ酸由来の植物性ミネラルおよびアミノ酸が、さらに含有されてなり、
前記アミノ酸が、アスパラギン酸、トリシリーナ、セリン、グルタミン酸、グリシリン、アラニン、シスチン、バリン、メチオリン、イワロリン、レウシン、チロシン、フェナリン、ヒスチジン、リシン、アンモニア、アレジン、プロリン、ロイシン、スレオニンである請求項1記載の血流改善剤。 - 鉱石から抽出されたミネラルを含む複数の微量元素が、さらに含有されてなり、
前記鉱石が、腐食花崗岩である請求項2記載の血流改善剤。 - 前記水が、酸素またはオゾンを溶存するナノバブル水である請求項1〜3のいずれか1項に記載の血流改善剤。
- 前記ナノコロイド化された海洋性有機化合物の気泡径が、30〜50nmである請求項1〜4のいずれか1項に記載の血流改善剤。
- 前記ナノコロイド化されたフルボ酸由来の植物性ミネラルおよびアミノ酸の気泡径が、30〜50nmで水中に分散されてなる請求項1〜5のいずれか1項に記載の血流改善剤。
- 前記酸素またはオゾンを溶存するナノバブル水の気泡径が、30〜50nmの気泡が水中に分散されてなる請求項1〜6のいずれか1項に記載の血流改善剤。
- 請求項1記載の血流改善剤の製造方法であって、
(1)逆浸透膜装置で純水を精製する工程と、
(2)(1)の工程で得られた精製水を容器に充填する工程と、
(3)ナノコロイド化された海洋性有機化合物を前記精製水に充填する工程とからなる、血流改善剤の製造方法。 - 請求項2記載の血流改善剤の製造方法であって、
(1)逆浸透膜装置で純水を精製する工程と、
(2)(1)の工程で得られた精製水を容器に充填する工程と、
(3)ナノコロイド化された海洋性有機化合物、フルボ酸由来の植物性のミネラルおよびアミノ酸を前記精製水に充填する工程とからなる、血流改善剤の製造方法。 - 請求項3記載の血流改善剤の製造方法であって、
(1)逆浸透膜装置で純水を精製する工程と、
(2)(1)の工程で得られた精製水を容器に充填する工程と、
(3)ナノコロイド化された海洋性有機化合物と、フルボ酸由来の植物性のミネラルおよびアミノ酸と、微量元素を前記精製水に充填する工程とからなる、血流改善剤の製造方法。 - 前記(1)の工程が、逆浸透膜装置で純水を精製し、酸素またはオゾンを溶存するナノバブル水に加工する工程であり、
前記(2)の工程が、酸素またはオゾンを溶存するナノバブル水で充填容器を洗浄した後、酸素またはオゾンを溶存するナノバブル水を容器に充填する工程である、請求項10記載の血流改善剤の製造方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009035658A JP2010189318A (ja) | 2009-02-18 | 2009-02-18 | 血流改善剤 |
PCT/JP2010/052464 WO2010095690A1 (ja) | 2009-02-18 | 2010-02-18 | 血流改善剤 |
US13/201,707 US20110300239A1 (en) | 2009-02-18 | 2010-02-18 | Blood flow improving agent |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009035658A JP2010189318A (ja) | 2009-02-18 | 2009-02-18 | 血流改善剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2010189318A true JP2010189318A (ja) | 2010-09-02 |
Family
ID=42633970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009035658A Pending JP2010189318A (ja) | 2009-02-18 | 2009-02-18 | 血流改善剤 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20110300239A1 (ja) |
JP (1) | JP2010189318A (ja) |
WO (1) | WO2010095690A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011016529A1 (ja) * | 2009-08-06 | 2011-02-10 | 株式会社協和機設 | 組成物およびその製造方法 |
JP2015092873A (ja) * | 2013-11-14 | 2015-05-18 | 奥長良川名水株式会社 | 密閉容器入り清涼飲料水の製造方法及び密閉容器入り清涼飲料水 |
WO2016084780A1 (ja) * | 2014-11-24 | 2016-06-02 | 有限会社中島工業 | 患部浸透亢進性薬剤組成物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3176131A4 (en) * | 2014-08-01 | 2018-03-21 | National Institute of Advanced Industrial Science and Technology | Ozone water and method for producing same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07238004A (ja) * | 1994-02-24 | 1995-09-12 | Asao Shimanishi | 殺菌消毒剤 |
JPH09252746A (ja) * | 1996-03-22 | 1997-09-30 | Nippon Kankyo Yakuhin Kk | 栄養補助食品 |
JP2003252785A (ja) * | 2002-03-01 | 2003-09-10 | Ako Kasei Co Ltd | 西洋人参混合物及びその製造法 |
JP2006087393A (ja) * | 2004-09-27 | 2006-04-06 | Global Science:Kk | 健康食品及び薬剤 |
JP2008214207A (ja) * | 2007-02-28 | 2008-09-18 | Sharp Corp | 血流量およびインスリン様成長因子増加装置、並びに血流量およびインスリン様成長因子増加方法 |
JP2008296095A (ja) * | 2007-05-29 | 2008-12-11 | Sharp Corp | 有用物質含有ナノバブル発生方法、および有用物質含有ナノバブル発生装置 |
-
2009
- 2009-02-18 JP JP2009035658A patent/JP2010189318A/ja active Pending
-
2010
- 2010-02-18 US US13/201,707 patent/US20110300239A1/en not_active Abandoned
- 2010-02-18 WO PCT/JP2010/052464 patent/WO2010095690A1/ja active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07238004A (ja) * | 1994-02-24 | 1995-09-12 | Asao Shimanishi | 殺菌消毒剤 |
JPH09252746A (ja) * | 1996-03-22 | 1997-09-30 | Nippon Kankyo Yakuhin Kk | 栄養補助食品 |
JP2003252785A (ja) * | 2002-03-01 | 2003-09-10 | Ako Kasei Co Ltd | 西洋人参混合物及びその製造法 |
JP2006087393A (ja) * | 2004-09-27 | 2006-04-06 | Global Science:Kk | 健康食品及び薬剤 |
JP2008214207A (ja) * | 2007-02-28 | 2008-09-18 | Sharp Corp | 血流量およびインスリン様成長因子増加装置、並びに血流量およびインスリン様成長因子増加方法 |
JP2008296095A (ja) * | 2007-05-29 | 2008-12-11 | Sharp Corp | 有用物質含有ナノバブル発生方法、および有用物質含有ナノバブル発生装置 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011016529A1 (ja) * | 2009-08-06 | 2011-02-10 | 株式会社協和機設 | 組成物およびその製造方法 |
JPWO2011016529A1 (ja) * | 2009-08-06 | 2013-01-17 | 株式会社Ligaric | 組成物およびその製造方法 |
JP2016013547A (ja) * | 2009-08-06 | 2016-01-28 | 株式会社Ligaric | 組成物およびその製造方法 |
JP2015092873A (ja) * | 2013-11-14 | 2015-05-18 | 奥長良川名水株式会社 | 密閉容器入り清涼飲料水の製造方法及び密閉容器入り清涼飲料水 |
WO2016084780A1 (ja) * | 2014-11-24 | 2016-06-02 | 有限会社中島工業 | 患部浸透亢進性薬剤組成物 |
JPWO2016084780A1 (ja) * | 2014-11-24 | 2017-11-02 | 有限会社中島工業 | 患部浸透亢進性薬剤組成物 |
Also Published As
Publication number | Publication date |
---|---|
US20110300239A1 (en) | 2011-12-08 |
WO2010095690A1 (ja) | 2010-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sharma et al. | Biogenic synthesis of nanoparticles: a review | |
US9162219B2 (en) | Fenton reaction catalyst produced using reducing organic substance as raw material | |
Stegemeier et al. | Speciation matters: Bioavailability of silver and silver sulfide nanoparticles to alfalfa (Medicago sativa) | |
Iravani | Green synthesis of metal nanoparticles using plants | |
AU2010260446B2 (en) | Compositions and methods for producing stable negative oxidation reduction potential in consumable materials | |
Pouri et al. | Biological synthesis of selenium nanoparticles and evaluation of their bioavailability | |
Bao et al. | Advances in biosynthesis of noble metal nanoparticles mediated by photosynthetic organisms—A review | |
WO2010095690A1 (ja) | 血流改善剤 | |
CN101917874A (zh) | 珊瑚粉的制备方法 | |
JP5754769B2 (ja) | 凝集処理方法 | |
Sarkar et al. | A state-of-the-art systemic review on selenium nanoparticles: Mechanisms and factors influencing biogenesis and its potential applications | |
Nam et al. | Novel treatment of Microcystis aeruginosa using chitosan-modified nanobubbles | |
Patel | Green synthesis of nanoparticles: a solution to environmental pollution | |
Bal | Invitro-invivo evaluations of green synthesized zinc oxide (ZnO) nanoparticles using Ipomoea aquatica leaf extract as matric and fillers | |
KR20200124598A (ko) | 카르복실산으로 유기화된 규소 이온 복합체 및 복합체의 제조방법과 이를 이용한 제품 | |
JP2013159593A (ja) | 溶岩粉末及び火山灰を用いた生体内の有毒物質及び放射性物質の無毒化方法及び汚染された田畑の改善方法 | |
Banaee et al. | Sublethal toxicity of TiO2 nanoparticles to common carp (Cyprinus carpio, Linnaeus, 1758) under visible light and dark conditions | |
Nam et al. | Antibacterial mechanism of phyto-synthesized CuO-decorated ZnO nanostructure in relation to hydrogen peroxide generation under visible-light condition | |
JP2017080741A (ja) | 還元性有機物を原料とするフェントン反応触媒 | |
JP2017177092A (ja) | 光触媒及び光触媒の製造方法 | |
JP2017108694A (ja) | 固形状乳酸発酵食品及びその製造方法 | |
CN101156832A (zh) | 一种矿物黑泥祛痘面膜及其生产方法 | |
JP2016000395A (ja) | 還元性有機物を原料とするフェントン反応触媒 | |
JP2006008645A (ja) | カバノアナタケエキスの製造方法 | |
JP6322956B2 (ja) | 鉄イオンを利用した光触媒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20110107 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20110201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110406 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110406 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110621 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110818 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111004 |